Literature DB >> 22889923

Another view of the history of antipsychotic drug discovery and development.

W T Carpenter1, J M Davis.   

Abstract

Chlorpromazine initiated effective pharmacotherapy for schizophrenia 60 years ago. This discovery initiated or stimulated key developments in the field of psychiatry. Nonetheless, advances in pharmacotherapy of schizophrenia have been modest. Psychosis remains the primary aspect of psychopathology addressed, and core pathologies such as cognition and negative symptom remain unmet therapeutic challenges. New clinical and basic neuroscience paradigms may guide the near future and provide a more heuristic construct for novel and innovative discovery.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22889923     DOI: 10.1038/mp.2012.121

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  14 in total

1.  A case of paranoid schizophrenia and severe antipsychotic-induced Parkinson's disorder treated with a combination of olanzapine and lurasidone.

Authors:  Oleg V Tcheremissine; Danielle Englert
Journal:  Innov Clin Neurosci       Date:  2013-09

2.  Involvement of anti-inflammatory, antioxidant, and BDNF up-regulating properties in the antipsychotic-like effect of the essential oil of Alpinia zerumbet in mice: a comparative study with olanzapine.

Authors:  Fernanda Yvelize Ramos de Araújo; Adriano José Maia Chaves Filho; Adriana Mary Nunes; Gersilene Valente de Oliveira; Patrícia Xavier Lima Gomes; Germana Silva Vasconcelos; Jaqueline Carletti; Manoel Odorico de Moraes; Maria Elisabete de Moraes; Silvânia Maria Mendes Vasconcelos; Francisca Cléa Florenço de Sousa; David Freitas de Lucena; Danielle S Macedo
Journal:  Metab Brain Dis       Date:  2021-09-07       Impact factor: 3.584

3.  The impact of second-generation antipsychotic adherence on positive and negative symptoms in recent-onset schizophrenia.

Authors:  Kenneth L Subotnik; Joseph Ventura; Denise Gretchen-Doorly; Gerhard S Hellemann; Elisha R Agee; Laurie R Casaus; John S Luo; Kathleen F Villa; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2014-08-06       Impact factor: 4.939

4.  Patterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review & assessment service-national patient sample.

Authors:  Seon-Cheol Park; Myung-Soo Lee; Seung-Gul Kang; Seung-Hwan Lee
Journal:  J Korean Med Sci       Date:  2014-04-25       Impact factor: 2.153

5.  Identification of SEC62 as a potential marker for 3q amplification and cellular migration in dysplastic cervical lesions.

Authors:  Maximilian Linxweiler; Florian Bochen; Bernhard Schick; Silke Wemmert; Basel Al Kadah; Markus Greiner; Andrea Hasenfus; Rainer-Maria Bohle; Ingolf Juhasz-Böss; Erich-Franz Solomayer; Zoltan Ferenc Takacs
Journal:  BMC Cancer       Date:  2016-08-23       Impact factor: 4.430

6.  Leveraging genome characteristics to improve gene discovery for putamen subcortical brain structure.

Authors:  Chi-Hua Chen; Yunpeng Wang; Min-Tzu Lo; Andrew Schork; Chun-Chieh Fan; Dominic Holland; Karolina Kauppi; Olav B Smeland; Srdjan Djurovic; Nilotpal Sanyal; Derrek P Hibar; Paul M Thompson; Wesley K Thompson; Ole A Andreassen; Anders M Dale
Journal:  Sci Rep       Date:  2017-11-16       Impact factor: 4.379

Review 7.  Translational Significance of Selective Estrogen Receptor Modulators in Psychiatric Disorders.

Authors:  Mohammad M Khan
Journal:  Int J Endocrinol       Date:  2018-10-08       Impact factor: 3.257

8.  Perspectives on reasons for non-adherence to medication in persons with schizophrenia in Ethiopia: a qualitative study of patients, caregivers and health workers.

Authors:  Solomon Teferra; Charlotte Hanlon; Teferra Beyero; Lars Jacobsson; Teshome Shibre
Journal:  BMC Psychiatry       Date:  2013-06-17       Impact factor: 3.630

9.  Targeting cell migration and the endoplasmic reticulum stress response with calmodulin antagonists: a clinically tested small molecule phenocopy of SEC62 gene silencing in human tumor cells.

Authors:  Maximilian Linxweiler; Stefan Schorr; Nico Schäuble; Martin Jung; Johannes Linxweiler; Frank Langer; Hans-Joachim Schäfers; Adolfo Cavalié; Richard Zimmermann; Markus Greiner
Journal:  BMC Cancer       Date:  2013-12-05       Impact factor: 4.430

Review 10.  Let's talk about Secs: Sec61, Sec62 and Sec63 in signal transduction, oncology and personalized medicine.

Authors:  Maximilian Linxweiler; Bernhard Schick; Richard Zimmermann
Journal:  Signal Transduct Target Ther       Date:  2017-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.